Here we produced expanded and activated NK cells (eNK)[7] and demonstrated that SDH‐rituximab i) stays in the presence of human polyclonal IgG; ii) increases eNK killing against targets; iii) together with a SDH‐CD19, protects mice from CD20/CD19 heterogeneous human tumor xenograft. This evidence concerns the gene CD19 and neoplasm.